Company intelligence / Profile preview
Oxxon Therapeutics
Oxford, United Kingdomoxti.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Oxxon Therapeutics was a clinical-stage biotechnology company specializing in the development of "PrimeBoost" immunotherapies for the treatment of chronic infectious diseases and cancer. The company's proprietary technology platform utilized a sequential administration of different vaccine delivery systems, such as DNA and viral vectors, to generate potent T-cell responses. Its lead candidate, Hi-8, was a therapeutic vaccine for melanoma that reached Phase 2 clinical trials. Oxxon was headquartered in Oxford, UK, with operations in Boston, Massachusetts. In 2007, the company was acquired by Oxford BioMedica to bolster its immunotherapy pipeline and expertise.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- VaccineDNA vaccineViral vector vaccine
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on Oxxon Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Oxxon Therapeutics.